Nektar Therapeutics (NKTR NASDAQ) stock market data APIs
$61.4201
-2.22(-3.6%)
as of October 22, 2025
Try our APIs with
free plan!
Nektar Therapeutics Financial Data Overview
Price chart is built with
Anychart
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Prev. Close
61.4201
Open
59.2044
High
61.705
Low
58.3738
52 wk Range
6.45-63.92
Market Cap
1 175 M
Shares Outstanding
19 019 K
Revenue
74 934 K
EPS
-2.78
Beta
1.197
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nektar Therapeutics (top by weight)
Ticker
100-day Price Change
Weight
POAGX.US
PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND PRIMECAP ODYSSEY AGGRESSIVE GROWTH FUND
6.72
(14.31%)
5.33
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nektar Therapeutics data using free add-ons & libraries
Get Nektar Therapeutics Fundamental Data
Nektar Therapeutics Fundamental data includes:
- Net Revenue: 74 934 K
- EBITDA: -137 164 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nektar Therapeutics News
New
IRON Gets Stronger, MNMD Sends A Soothing Signal To Investors, Will Christmas Come Early For NKTR?
(RTTNews) - "Returns matter a lot. It's our capital," said Abigail Johnson, chief executive of Fidelity Investments - a powerful reminder that successful investing isn't just about owning stocks, but ...
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Key Points Nektar Therapeutics' leading candidate is performing well so far in phase 2 studies. This medicine could disrupt the large and competitive eczema treatment market. Nektar could match Wall ...
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Key Points Last month, Nektar Therapeutics presented results for its experimental eczema treatment. The eczema treatment Nektar Therapeutics is developing helped a surprising percentage of patients a...
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Key Points Shares of Nektar Therapeutics and Mineralys Therapeutics have risen sharply, and could run even further. Nektar is developing an experimental eczema treatment. Millions of patients with st...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
